Emplicure AB Year-end report 2022
2023-02-23 07:05
FOURTH QUARTER, OCTOBER-DECEMBER 2022
- Net sales amounted to MSEK 0.0 (0.0)
- Operating loss (EBIT) amounted to MSEK -9.4 (-5.2)
- Net loss amounted to MSEK -9.0 (-5.1)
- Net cash flow amounted to MSEK +0.2 (-4.6)
- EPS before and after dilution amounted to SEK -0.34 (-0.25)
JANUARY-DECEMBER 2022
- Net sales amounted to MSEK 0.0 (0.1)
- Operating loss (EBIT) amounted to MSEK -29.9 (-16.7)
- Net loss amounted to MSEK -29.5 (-18.4)
- Net cash flow amounted to MSEK -8.9 (+18.8)
- EPS before and after dilution amounted to SEK -1.22 (-1.16)
This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on February 23, 2023 at 08:05 CET
For additional information, please contact
Håkan Engqvist
CEO
Phone: +46 702 569 500
Email: hakan.engqvist@emplicure.com
Erik Magnusson
CFO
Phone: +46 708 565 245
Email: erik.magnusson@emplicure.com
Certified Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.
The following documents can be retrieved from beQuoted
Emplicure-Q422 ENG FINAL.pdf
Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com